There are 2789 resources available
48P - (BREGO) Regorafenib combined with modified m-GEMOX in patients with advanced biliary tract cancer (BTC): A phase II randomized trial
Presenter: Eric Assenat
Session: ePoster Display
49P - A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
Presenter: Nai-Jung Chiang
Session: ePoster Display
51P - Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)
Presenter: Funda Meric-Bernstam
Session: ePoster Display
52P - Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA)
Presenter: Antoine Hollebecque
Session: ePoster Display
53P - FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma
Presenter: Xiao-Wu Huang
Session: ePoster Display
54P - Assessment of EU4 laboratory readiness for FGFR2 fusion testing of cholangiocarcinoma by NGS
Presenter: Marianna Sciortino
Session: ePoster Display
55P - Integrative genomic analysis identified primary cilium-associated genes by as novel key genes in biliary tract cancer (BTC)
Presenter: Massimiliano Salati
Session: ePoster Display
56P - Serum protein signatures as potential novel diagnostic biomarkers for biliary tract cancer
Presenter: Troels Christensen
Session: ePoster Display
57P - The characteristics of IDH mutations in Chinese bile duct carcinoma patients
Presenter: Yuwen Wang
Session: ePoster Display